Display options
Cite
Desai N, Venkatesh CR, Kumar SS. QT prolongation and torsades de pointes with psychotropic agents. Indian J Psychiatry. 2015;57(3):305-8doi: 10.4103/0019-5545.166619.
Desai, N., Venkatesh, C. R., & Kumar, S. S. (2015). QT prolongation and torsades de pointes with psychotropic agents. Indian journal of psychiatry, 57(3), 305-8. https://doi.org/10.4103/0019-5545.166619
Desai, Nagaraj, et al. "QT prolongation and torsades de pointes with psychotropic agents." Indian journal of psychiatry vol. 57,3 (2015): 305-8. doi: https://doi.org/10.4103/0019-5545.166619
Desai N, Venkatesh CR, Kumar SS. QT prolongation and torsades de pointes with psychotropic agents. Indian J Psychiatry. 2015 Jul-Sep;57(3):305-8. doi: 10.4103/0019-5545.166619. PMID: 26600587; PMCID: PMC4623652.
Copy Download .nbib Format: NLM
Share it on

Indian J Psychiatry. 2015 Jul-Sep;57(3):305-8. doi: 10.4103/0019-5545.166619.

QT prolongation and torsades de pointes with psychotropic agents.

Indian journal of psychiatry

Nagaraj Desai, Chilkunda Raviprakash Venkatesh, Shambu Sunil Kumar

Affiliations

  1. Department of Cardiology and Head, Department of Cardiovascular and Thoracic Sciences, JSS Medical College and Hospital, JSS University, Mysuru, Karnataka, India.
  2. Department of Medicine, JSS Medical College and Hospital, JSS University, Mysuru, Karnataka, India.
  3. Department of Cardiology, JSS Medical College and Hospital, JSS University, Mysuru, Karnataka, India.

PMID: 26600587 PMCID: PMC4623652 DOI: 10.4103/0019-5545.166619

Abstract

The unexpected and catastrophic cardiovascular effects of psychotropic drugs are well described albeit uncommon. The list of drugs which have been associated with prolonging QT interval and hence potentially causing Torsades de pointes is exhaustive. The insight into the plausible mechanisms are largely unclear. However, the practical implications of anticipating and recognizing QT prolongation cannot be overemphasized.

Keywords: Psychotropic agents; QT interval; torsades de pointes

References

  1. Hum Exp Toxicol. 2011 Oct;30(10 ):1649-56 - PubMed
  2. Clin Ther. 2011 Jul;33(7):851-62 - PubMed
  3. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51 - PubMed
  4. Lancet. 2000 Mar 25;355(9209):1048-52 - PubMed
  5. Ann Pharmacother. 2014 Dec;48(12):1620-8 - PubMed
  6. J Clin Psychopharmacol. 2013 Feb;33(1):3-10 - PubMed
  7. Int J Neuropsychopharmacol. 2014 Oct 31;18(4):null - PubMed
  8. BMJ. 2013 Jan 29;346:f288 - PubMed
  9. Clin Pharmacol Ther. 2001 Sep;70(3):261-9 - PubMed
  10. J Clin Psychopharmacol. 2009 Feb;29(1):9-15 - PubMed
  11. Am J Health Syst Pharm. 2008 Jun 1;65(11):1029-38 - PubMed
  12. Dtsch Arztebl Int. 2011 Oct;108(41):687-93 - PubMed
  13. N Engl J Med. 2004 Mar 4;350(10):1013-22 - PubMed
  14. J Clin Psychopharmacol. 2013 Apr;33(2):157-61 - PubMed
  15. Ther Adv Psychopharmacol. 2015 Feb;5(1):26-31 - PubMed
  16. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):401-5 - PubMed
  17. J Addict Dis. 2013;32(3):244-51 - PubMed
  18. Wien Klin Wochenschr. 2008;120(5-6):128-35 - PubMed
  19. Br J Clin Pharmacol. 2008 Sep;66(3):396-404 - PubMed
  20. J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53 - PubMed
  21. Pediatr Neurol. 2004 Feb;30(2):99-101 - PubMed
  22. Am Heart J. 2007 Jun;153(6):891-9 - PubMed
  23. Clin Ther. 2012 Feb;34(2):351-362.e3 - PubMed
  24. Sci Rep. 2013;3:2100 - PubMed
  25. Fed Regist. 2005 Oct 20;70(202):61134-5 - PubMed
  26. Drugs. 2012 Jan 1;72(1):133-62 - PubMed
  27. Psychosomatics. 2013 Jan-Feb;54(1):1-13 - PubMed
  28. Br J Clin Pharmacol. 2013 Jul;76(1):48-57 - PubMed
  29. Drug Saf. 2013 Mar;36(3):167-82 - PubMed

Publication Types